tert-butyl (S)-3-((benzyloxy)carbonyl)-1-(4-(octyloxy)phenylcarbamoyl)propylcarbamate | 876914-13-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: tert-butyl (S)-3-((benzyloxy)carbonyl)-1-(4-(octyloxy)phenylcarbamoyl)propylcarbamate
• 英文别名: benzyl (4S)-4-[(2-methylpropan-2-yl)oxycarbonylamino]-5-(4-octoxyanilino)-5-oxopentanoate
• CAS: 876914-13-5
• 化学式: C₃₁H₄₄N₂O₆
• 分子量: 540.7
• InChiKey: FKZHRYCMERFOOP-MHZLTWQESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.9
• 重原子数：
  39
• 可旋转键数：
  19
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  103
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  tert-butyl (S)-3-((benzyloxy)carbonyl)-1-(4-(octyloxy)phenylcarbamoyl)propylcarbamate 在 palladium 10% on activated carbon 、 氢气 、 三氟乙酸 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 生成 (S)-4-(4-(octyloxy)phenylcarbamoyl)-4-aminobutanoic acid
  参考文献：
  名称：

  Exploring amino acids derivatives as potent, selective, and direct agonists of sphingosine-1-phosphate receptor subtype-1

  摘要：

  In the quest to discover a potent and selective class of direct agonists to the sphingosine-1-phosphate receptor, we explored the carboxylate functional group as a replacement to previously reported lead phosphates. This has led to the discovery of potent and selective direct agonists with moderate to substantial in vivo lymphopenia. The previously reported selectivity enhancing moiety (SEM) and selectivity enhancing orientation (SEO) in the phenylamide and phenylimidazole scaffolds were crucial to obtaining selectivity for S1P receptor subtype 1 over 3. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.11.053

文献信息

• Methods and compositions for modulating sphingosine -1- phosphate (S1P) receptor activity
  申请人：Saha K. Ashis

  公开号：US20080064662A1

  公开（公告）日：2008-03-13

  The present invention relates to compounds which modulate the activity of the S1P1 receptor, the use of these compounds for treating conditions associated with signaling through the S1P1 receptor, and pharmaceutical compositions comprising these compounds.

  本发明涉及调节S1P1受体活性的化合物，使用这些化合物治疗与S1P1受体信号有关的疾病，并包括这些化合物的制药组合物。
• US7241812B2
  申请人：——

  公开号：US7241812B2

  公开（公告）日：2007-07-10